These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 33539184)

  • 1. The COVID-19 Innovation System.
    Sampat BN; Shadlen KC
    Health Aff (Millwood); 2021 Mar; 40(3):400-409. PubMed ID: 33539184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How New Models Of Vaccine Development For COVID-19 Have Helped Address An Epic Public Health Crisis.
    Bloom DE; Cadarette D; Ferranna M; Hyer RN; Tortorice DL
    Health Aff (Millwood); 2021 Mar; 40(3):410-418. PubMed ID: 33539191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Access to anti-covid vaccines: research, development and role of patents.].
    Formoso G; Mancini S
    Recenti Prog Med; 2021; 112(7):499-503. PubMed ID: 34263876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Access considerations for a COVID-19 vaccine for South Africa.
    Bangalee V; Suleman F
    S Afr Fam Pract (2004); 2020 Oct; 62(1):e1-e4. PubMed ID: 33179954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.
    Farlow A; Torreele E; Gray G; Ruxrungtham K; Rees H; Prasad S; Gomez C; Sall A; Magalhães J; Olliaro P; Terblanche P
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Warp-Speed Covid-19 Vaccine Development: Beneficiaries of Maturation in Biopharmaceutical Technologies and Public-Private Partnerships.
    Ho RJY
    J Pharm Sci; 2021 Feb; 110(2):615-618. PubMed ID: 33212162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct from the COVID-19 crisis: research and innovation sparks in Brazil.
    Rosa MFF; da Silva EN; Pacheco C; Diógenes MVP; Millett C; Gadelha CAG; Santos LMP
    Health Res Policy Syst; 2021 Jan; 19(1):10. PubMed ID: 33478499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Into the valley of death: research to innovation.
    Hudson J; Khazragui HF
    Drug Discov Today; 2013 Jul; 18(13-14):610-3. PubMed ID: 23402848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic.
    Neumann PJ; Cohen JT; Kim DD; Ollendorf DA
    Health Aff (Millwood); 2021 Jan; 40(1):53-61. PubMed ID: 33211534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biopharmaceutical Financialization and Public Funding of Medical Countermeasures (MCMs) in Canada During the COVID-19 Pandemic.
    Eren Vural I; Herder M; Doll A; Graham JE
    Int J Health Policy Manag; 2023; 12():6936. PubMed ID: 37579382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barriers Influencing Vaccine Development Timelines, Identification, Causal Analysis, and Prioritization of Key Barriers by KOLs in General and Covid-19 Vaccine R&D.
    Janse M; Brouwers T; Claassen E; Hermans P; van de Burgwal L
    Front Public Health; 2021; 9():612541. PubMed ID: 33959579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 Digital Health Innovation Policy: A Portal to Alternative Futures in the Making.
    Bayram M; Springer S; Garvey CK; Özdemir V
    OMICS; 2020 Aug; 24(8):460-469. PubMed ID: 32511054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of the Private Sector in the COVID-19 Pandemic: Experiences From Four Health Systems.
    Wallace LJ; Agyepong I; Baral S; Barua D; Das M; Huque R; Joshi D; Mbachu C; Naznin B; Nonvignon J; Ofosu A; Onwujekwe O; Sharma S; Quayyum Z; Ensor T; Elsey H
    Front Public Health; 2022; 10():878225. PubMed ID: 35712320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Realizing Public Rights Through Government Patent Use.
    Kapczynski A
    J Law Med Ethics; 2021; 49(1):34-38. PubMed ID: 33966648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of South Africa's public-private partnership for the localisation of vaccine research, manufacture and distribution.
    Walwyn DR; Nkolele AT
    Health Res Policy Syst; 2018 Mar; 16(1):30. PubMed ID: 29587777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mobile health clinic model in the COVID-19 pandemic: lessons learned and opportunities for policy changes and innovation.
    Attipoe-Dorcoo S; Delgado R; Gupta A; Bennet J; Oriol NE; Jain SH
    Int J Equity Health; 2020 May; 19(1):73. PubMed ID: 32429920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Public Risk-Taking and Rewards During the COVID-19 Pandemic - A Case Study of Remdesivir in the Context of Global Health Equity.
    Wimmer S; Keestra SM
    Int J Health Policy Manag; 2022 May; 11(5):567-578. PubMed ID: 32945638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From COVID-19 research to vaccine application: why might it take 17 months not 17 years and what are the wider lessons?
    Hanney SR; Wooding S; Sussex J; Grant J
    Health Res Policy Syst; 2020 Jun; 18(1):61. PubMed ID: 32513202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing Pull Funding For A COVID-19 Vaccine.
    Snyder CM; Hoyt K; Gouglas D; Johnston T; Robinson J
    Health Aff (Millwood); 2020 Sep; 39(9):1633-1642. PubMed ID: 32701395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.